SCPX (Scorpius Holdings) YoY EBITDA Growth: 100.49% (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Scorpius Holdings YoY EBITDA Growth?

Scorpius Holdings SCPX YoY EBITDA Growth is 100.49% as of Sep. 2025. The stock has 7 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Scorpius Holdings's YoY EBITDA Growth for the quarter that ended in Sep. 2025 was 100.49%.

Scorpius Holdings's EBITDA per Share for the three months ended in Sep. 2025 was $0.01.

Scorpius Holdings YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Scorpius Holdings's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scorpius Holdings YoY EBITDA Growth Chart

Scorpius Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.53 13.84 -9.69 12.23 96.13

Scorpius Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.02 95.71 94.48 99.73 100.49

Scorpius Holdings YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Scorpius Holdings's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-10.423--269.383)/ | -269.383 |
=96.13 %

Scorpius Holdings's YoY EBITDA Growth for the quarter that ended in Sep. 2025 is calculated as:

YoY EBITDA Growth (Q: Sep. 2025 )
=(EBITDA per Share (Q: Sep. 2025 )-EBITDA per Share (Q: Sep. 2024 )) / | EBITDA per Share (Q: Sep. 2024 )) |
=(0.006--1.216)/ | -1.216 |
=100.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 100.49% mean?
Scorpius Holdings (SCPX) has a YoY EBITDA Growth of 100.49% as of Sep. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Scorpius Holdings and its competitors.
Is Scorpius Holdings' YoY EBITDA Growth too high?
Scorpius Holdings' current YoY EBITDA Growth is 100.49%.
How does Scorpius Holdings' YoY EBITDA Growth compare to CARM and PKTX?
Scorpius Holdings' YoY EBITDA Growth of 100.49% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Scorpius Holdings and its competitors. Scorpius Holdings's current YoY EBITDA Growth is 100.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scorpius Holdings stock overvalued right now?
Based on GuruFocus' analysis, Scorpius Holdings (SCPX) is currently considered Possible Value Trap. The stock's GF Value™ is $0.07, compared to a current price of $0.00 — trading 98.6% below its estimated fair value. The current YoY EBITDA Growth is 100.49%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Scorpius Holdings (SCPX), the current YoY EBITDA Growth is 100.49% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scorpius Holdings Business Description

Address 1305 East Houston Street, San Antonio, TX, USA, 27560
Scorpius Holdings Inc is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state of the art facilities.